Liraglutide reduces fibrosis in human cirrhotic liver slices via HSC deactivation and ECM remodeling.
Background
The progression of chronic liver disease (CLD), particularly hepatic fibrosis and cirrhosis, is driven by excessive extracellular matrix (ECM) remodeling, primarily by activated hepatic stellate cells (HSCs). Current standard-of-care often falls short in reversing advanced fibrosis, necessitating novel therapeutic strategies. While precision-cut liver slices (PCLS) offer a relevant ex vivo model, their short viability limits long-term studies. Microfluidic platforms address this by improving tissue preservation and mimicking in vivo liver dynamics, providing a robust model to test antifibrotic agents like liraglutide, which has shown promise in non-cirrhotic patients.
Study Design
Researchers established a microfluidic human PCLS model using human cirrhotic PCLS (from ALD/MetALD patients) cultured under static or microfluidic conditions for 7 days. They evaluated viability, necrosis, fibrosis, and liver function. Collagen composition was analyzed across healthy, compensated, and decompensated liver samples. Cirrhotic PCLS were then treated with liraglutide 200 µM or vehicle, followed by comprehensive transcriptomic and proteomic analyses to assess antifibrotic effects and underlying mechanisms.
Results
Microfluidic culture significantly improved tissue integrity, reduced necrosis and fibrosis, and enhanced sinusoidal cell communication in human cirrhotic PCLS over 7 days. Analysis of human liver samples revealed that major collagens were upregulated in decompensated cirrhosis, while COL10α1 increased early in compensated stages, suggesting its role as a sensitive biomarker. Importantly, treatment with liraglutide 200 µM demonstrated potent antifibrotic activity.
Liraglutide reduced fibrosis and rebalanced hepatic stellate cells (HSCs) phenotype, likely through metabolic reprogramming linked to the inhibition of
AKT signaling. This antifibrotic effect was notably independent ofGLP1Rsignaling, suggesting a novel, direct mechanism of action within the liver tissue. The study also confirmedCOL10α1as a promising biomarker for both fibrosis progression and regression.
Key Findings
- Microfluidic culture improved human cirrhotic liver slice integrity, reducing necrosis and fibrosis over 7 days.
- Liraglutide 200 µM reduced fibrosis and rebalanced hepatic stellate cell (HSC) phenotype in cirrhotic slices.
- Liraglutide's antifibrotic effects were linked to metabolic reprogramming and inhibition of
AKT signaling. - The antifibrotic action of liraglutide was independent of
GLP1Rsignaling. COL10α1emerged as a sensitive biomarker for fibrosis progression and regression.
Why It Matters
This study provides a robust ex vivo platform for evaluating antifibrotic therapies and highlights a novel, direct antifibrotic mechanism for liraglutide in advanced liver disease. Liraglutide's ability to deactivate HSCs and remodel ECM, independent of GLP-1R, suggests its potential utility even in patients with severe fibrosis or cirrhosis where systemic GLP-1R activation might be less relevant or tolerated. This opens avenues for repurposing liraglutide or developing GLP-1R-independent analogs for hepatic fibrosis. Furthermore, COL10α1 emerges as a valuable biomarker, potentially guiding treatment decisions and monitoring response to antifibrotic interventions, moving us closer to personalized medicine for chronic liver disease.
liraglutide
hepatic-fibrosis
cirrhosis
hsc-deactivation
ecm-remodeling
in-vitro